About

palfreyman

Michael G Palfreyman, PhD, DSc, MRPharmS
USA, Boston        +1 (978) 884-4861

CV Michael G Palfreyman

Michael G Palfreyman is a Boston (USA) based Associate Partner.

Michael is a seasoned leader in the biotechnology and pharmaceutical industries with over 40 years’ experience in leadership positions. He specializes in leading and guiding life sciences companies regarding their strategy, financing, BD&L activities and product development. In this capacity Michael currently serves as the Chairman of the Board of Amakem, NV and Ophthakem, NV; as Director of Oculogics, Inc and a Member of the Patent Review Board, Forsyth Dental Institute. In addition to these positions, he is the Head of R&D Diligence at Torrey Pines Investment and Senior R&D Diligence at ChemRar; the Head of Translational R&D at ChemDiv, Inc., Chief Scientific Officer at Amorsa Therapeutics, Inc., as well as Scientific Advisor for EnVivo Pharmaceuticals, Inc., Avineuro,Inc., NeuroNascent, Inc., Jasco Pharmaceuticals, Inc., and the Chairman of the SAB at Aminex Therapeutics, Inc.

Michael is a Fellow of the American College of Neuropsychopharmacology. Although Michael’s passion lies in the CNS field he has not only overseen several research programs in Psychiatric and Neurological, but also in Cardiovascular, Cancer, Infectious, Metabolic and Respiratory Disorders.

Michael held several key roles from President & CSO to Head of Biotechnology licensing, in successful Biotech and Pharmaceutical companies, such as EnVivo Pharmaceuticals, NOVACE Corporation, Psychiatric Genomics, Scriptgen (now Anadys) Pharmaceuticals, as well as Marion Merrell Dow Research Institute (now Sanofi) and Beecham Pharmaceuticals (now Glaxo Smith Kline).

Dr. Palfreyman’s own research included discovery and development of a number of psychotherapeutic compounds for treatment of psychosis, depression, stroke, epilepsy, emesis, Parkinson’s, Alzheimer’s and Huntington’s diseases. Many of these compounds have entered clinical development and a number have reached the marketplace.

Michael holds a D.Sc. (1996), and a Ph.D. (1970) degree in Pharmacology as well as a B.Pharm(Hons), and a M.R. Pharm.S, all from the University of Nottingham, UK.

Back